|
In
the business of discovery
Sudarshan Arora, President-NCE Research, Lupin reveals the
nuances of NCE research in India and the company’s
competencies in conversation with Katya Naidu.
Breaking
the myth
Erbitux the latest drug released by Merck KGaA slipped into
controversy regarding the interpretation the results of a
study. The drug is a monoclonal antibody targeting the epidermal
growth factor receptor (EGFR).
‘Cost
should not affect personalised medicine’
The future of pharmaceutical research is looking at therapies
which will be tailor-made to individuals. Harish Padh talks
to Katya Naidu about the benefits of pharmacogenomics.
|
